Showing results (1241-1250 of 2,691) with videos related to

Sort By:
Pageof 270
The Lancet. Infectious Diseases|October 13, 2024
Adjunctive linezolid versus clindamycin for toxin inhibition in β-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: a retrospective cohort study with target trial emulationAhmed Babiker, Sarah Warner, Xiaobai Li, et al.
The Lancet. Infectious Diseases|October 10, 2024
Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trialMatthijs P Raadsen, Christine Dahlke, Anahita Fathi, et al.
The Lancet. Infectious Diseases|October 10, 2024
New WHO guidelines for treating rhodesiense human African trypanosomiasis: expanded indications for fexinidazole and pentamidineAndreas K Lindner, Veerle Lejon, Michael P Barrett, et al.
The Lancet. Infectious Diseases|October 10, 2024
Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trialYehuda Carmeli, José Miguel Cisneros, Mical Paul, et al.
The Lancet. Infectious Diseases|September 7, 2024
The evidence base for the optimal antibiotic treatment duration of upper and lower respiratory tract infections: an umbrella reviewSuzanne M E Kuijpers, David T P Buis, Kirsten A Ziesemer, et al.
The Lancet. Infectious Diseases|August 8, 2024
Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in BrazilMauricio L Nogueira, Monica A T Cintra, José A Moreira, et al.
The Lancet. Infectious Diseases|July 19, 2024
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trialSanthosh Kumar Ghadge, Martina Schneider, Katrin Dubischar, et al.
The Lancet. Infectious Diseases|July 22, 2024
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trialGlenda E Gray, Kathryn Mngadi, Ludo Lavreys, et al.
The Lancet. Infectious Diseases|July 28, 2024
Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trialIsabel Leroux-Roels, Chittappen Kandiyil Prajeeth, Amare Aregay, et al.
The Lancet. Infectious Diseases|July 4, 2024
Measures to prevent and treat Nipah virus disease: research priorities for 2024-29Kristine A Moore, Angela J Mehr, Julia T Ostrowsky, et al.
Pageof 270